Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.

Author information

Affiliations

  • 1. Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
      Authors
    • Green AR 1
    • Aleskandarany MA 1
    • Hodgson EG 1
    • Atabani S 1
    • Rakha EA 1
    • Ellis IO 1
    (6 authors)
  • 2. Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
      Authors
    • Ali R 2
    • Madhusudan S 2, 3
    (2 authors)
  • 3. Department of Oncology, Nottingham University Hospitals, Nottingham, United Kingdom.
      Authors
    • De Souza K 3
    • Madhusudan S 2, 3
    (2 authors)

ORCIDs linked to this article

Cancer Immunology Research, 02 Mar 2017, 5(4):292-299
https://doi.org/10.1158/2326-6066.cir-16-0195 PMID: 28254786 

Abstract 

Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand break repair (BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO2A, DNA-PKcs, Ku70/Ku80), nucleotide excision repair (ERCC1), base excision repair (XRCC1, pol β, FEN1, PARP1), and immune responses (CD8, PD-1, PD-L1, FOXP3) in 1,269 breast cancers and validated our findings in an independent estrogen receptor-negative (ER-) cohort (n = 279). Patients with tumors that expressed low XRCC1, low ATM, and low BRCA1 were not only associated with high numbers of CD8+ tumor-infiltrating lymphocytes, but were also linked to higher grades, high proliferation indexes, presence of dedifferentiated cells, ER- cells, and poor survival (all P ≤ 0.01). PD-1+ or PD-L1+ breast cancers with low XRCC1 were also linked to an aggressive phenotype that was high grade, had high proliferation indexes, contained dedifferentiated cells and ER- (all with P values ≤ 0.01), and poor survival (P = 0.00021 and P = 0.00022, for PD-1+ and PD-L1+ cancers, respectively) including in an independent ER- validation cohort (P = 0.007 and P = 0.047, respectively). We conclude that the interplay between DNA repair, CD8, PD-L1, and PD-1 can promote aggressive tumor phenotypes. XRCC1-directed personalization of immune checkpoint inhibitor therapy may be feasible and warrants further investigation in breast cancer. Cancer Immunol Res; 5(4); 292-9. ©2017 AACR.

Full text links 

Read article at publisher's site: https://doi.org/10.1158/2326-6066.cir-16-0195

Read article for free, from open access legal sources, via Unpaywall: https://cancerimmunolres.aacrjournals.org/content/canimm/5/4/292.full.pdfUnpaywall

Citations & impact 

Impact metrics

39
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/43526327
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/43526327

Article citations

Go to all (39) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.